{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:39:36Z","timestamp":1793263176070,"version":"4.5.0"},"reference-count":20,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"Data Sciences Institute at the University of Toronto"},{"DOI":"10.13039\/100013528","name":"Diabetes Canada","doi-asserted-by":"publisher","award":["OG-3-21-5572-BP"],"award-info":[{"award-number":["OG-3-21-5572-BP"]}],"id":[{"id":"10.13039\/100013528","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Rather than during illness while diabetic ketoacidosis (DKA) is developing, we aimed to determine if levels of routine point-of-care capillary blood ketones could predict future DKA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>We examined previously collected data from placebo-assigned participants in an adjunct-to-insulin medication trial program that included measurement of fasted capillary blood ketone levels twice per week in a 2-month baseline period. The outcome was 6- to 12-month trial-adjudicated DKA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>DKA events occurred in 12 of 484 participants at a median of 105 (interquartile range 43, 199) days. Maximum ketone levels were higher in patient cases compared with in control patients (0.8 [0.6, 1.2] vs. 0.3 [0.2, 0.7] mmol\/L; P = 0.002), with a nonparametric area under the receiver operating characteristic curve of 0.77 (95% CI 0.66\u20130.88). Ketone levels \u22650.8 mmol\/L had a sensitivity of 64%, a specificity of 78%, and positive and negative likelihood ratios of 2.9 and 0.5, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>This proof of concept that routine capillary ketone surveillance can identify individuals at high risk of future DKA implies a role for future technologies including continuous ketone monitoring.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc23-0840","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T18:04:19Z","timestamp":1692900259000},"page":"1973-1977","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":25,"title":["Point-of-Care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes"],"prefix":"10.2337","volume":"46","author":[{"given":"Cimon","family":"Song","sequence":"first","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Dhaliwal","sequence":"additional","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Bapat","sequence":"additional","affiliation":[{"name":"2Division of General Internal Medicine, Department of Medicine, University Health Network and Sinai Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Scarr","sequence":"additional","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmohsen","family":"Bakhsh","sequence":"additional","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"3Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"4Kidney & Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton","family":"Budhram","sequence":"additional","affiliation":[{"name":"2Division of General Internal Medicine, Department of Medicine, University Health Network and Sinai Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha J.","family":"Verhoeff","sequence":"additional","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Weisman","sequence":"additional","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"3Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"5Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fralick","sequence":"additional","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"2Division of General Internal Medicine, Department of Medicine, University Health Network and Sinai Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah M.","family":"Ivers","sequence":"additional","affiliation":[{"name":"5Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada"},{"name":"6Department of Family and Community Medicine, Women\u2019s College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[{"name":"7Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"8Biostatistics Research Unit, University Health Network, Toronto, Ontario, Canada"},{"name":"9Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Erik","family":"Lovblom","sequence":"additional","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"3Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"9Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Mumford","sequence":"additional","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-0046","authenticated-orcid":false,"given":"Bruce A.","family":"Perkins","sequence":"additional","affiliation":[{"name":"1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"3Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"2023102718510490400_B1","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2013-1589","article-title":"Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry","volume":"98","author":"Weinstock","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2023102718510490400_B2","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.2337\/dc15-0780","article-title":"Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany","volume":"38","author":"Maahs","year":"2015","journal-title":"Diabetes Care"},{"key":"2023102718510490400_B3","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"2023102718510490400_B4","unstructured":"U.S. Food and Drug Administration\n          . 510(k) Substantial Equivalence Determination Decision Summary Assay and Instrument Combination Template. Accessed 11 July 2023. Available from https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K080960.pdf"},{"key":"2023102718510490400_B5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"2023102718510490400_B6","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2337\/dc10-1844","article-title":"Diagnostic accuracy of point-of-care testing for diabetic ketoacidosis at emergency-department triage: beta-hydroxybutyrate versus the urine dipstick","volume":"34","author":"Arora","year":"2011","journal-title":"Diabetes Care"},{"key":"2023102718510490400_B7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/dc07-1683","article-title":"Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?","volume":"31","author":"Sheikh-Ali","year":"2008","journal-title":"Diabetes Care"},{"key":"2023102718510490400_B8","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jcjd.2017.10.013","article-title":"Hyperglycemic emergencies in adults","volume":"42","author":"Goguen","year":"2018","journal-title":"Can J Diabetes"},{"key":"2023102718510490400_B9","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"key":"2023102718510490400_B10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI107839","article-title":"Hepatic ketogenesis and gluconeogenesis in humans","volume":"54","author":"Garber","year":"1974","journal-title":"J Clin Invest"},{"key":"2023102718510490400_B11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/19322968211008185","article-title":"Feasibility of continuous ketone monitoring in subcutaneous tissue using a ketone sensor","volume":"15","author":"Alva","year":"2021","journal-title":"J Diabetes Sci Technol"},{"key":"2023102718510490400_B12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/19322968211042656","article-title":"Continuous ketone monitoring consensus report 2021","volume":"16","author":"Nguyen","year":"2022","journal-title":"J Diabetes Sci Technol"},{"key":"2023102718510490400_B13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S2213-8587(20)30042-5","article-title":"Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes","volume":"8","author":"Ehrmann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023102718510490400_B14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrendo.2016.15","article-title":"Diabetic emergencies: ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia","volume":"12","author":"Umpierrez","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2023102718510490400_B15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41572-020-0165-1","article-title":"Diabetic ketoacidosis","volume":"6","author":"Dhatariya","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2023102718510490400_B16","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.2337\/dc23-S006","article-title":"6. Glycemic targets: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2023102718510490400_B17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023102718510490400_B18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/dia.2018.0246","article-title":"Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"2023102718510490400_B19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"key":"2023102718510490400_B20","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/dom.13811","article-title":"Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/11\/1973\/737025\/dc230840.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/11\/1973\/737025\/dc230840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T18:53:06Z","timestamp":1698432786000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/46\/11\/1973\/153541\/Point-of-Care-Capillary-Blood-Ketone-Measurements"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,8,24]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-0840","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}